Chemotherapy News and Research

Latest Chemotherapy News and Research

The Cancer Center at Harrington receives approval to treat its first patients

The Cancer Center at Harrington has received approval to treat its first patients, Harrington Hospital announced today.

4 Dec 2009

Update on European commercial launch of MuGard for oral mucositis provided

ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP), today provided an update on its European commercial launch of MuGard, an FDA approved treatment for oral mucositis, a debilitating side effect of radiation treatment and chemotherapy.

4 Dec 2009

Don't stop dieting during the holiday season

As Americans gear up for the holiday season this month, Dr. Sasson Moulavi, a Board Certified Bariatric Physician, cautions that overweight and obese patients not give in to temptation and forget their dieting. Rather, Dr. Sass, founder of the Smart for Life(R) Cookie Diet, recommends alternative behavior for a positive outcome when it is time to ring in the New Year.

3 Dec 2009

Allos Therapeutics to launch the COMPLETE registry for patients with PTCL

Allos Therapeutics, Inc. today announced the launch of an international registry designed to address the urgent need to better understand treatment patterns and outcomes for patients with peripheral T-cell lymphoma (PTCL). The registry, known as COMPLETE (Comprehensive Oncology Measures for Peripheral T-cell Lymphoma Treatment), is a global observational study that will enroll patients with newly-diagnosed PTCL and obtain data regarding longitudinal treatment patterns and outcomes.

3 Dec 2009

Update on Celsion's ThermoDox Phase III “HEAT” trial for HCC

Celsion Corporation, a leading oncology drug development company, today provided an update on the progress of its pivotal ThermoDox® Phase III “HEAT” trial for the treatment of hepatocellular carcinoma (HCC), the most common form of primary liver cancer. Following recent regulatory approvals in China, Malaysia, Thailand and the Philippines, the study is now enrolling patients in eleven countries, with the majority of clinical sites located in the Asia Pacific region where HCC is most prevalent.

3 Dec 2009

PEG polymer may prevent GI injury during cancer radiotherapy

A non-absorbed, oral co-polymer therapy under development by Midway Pharmaceuticals demonstrated the ability to protect against damage to healthy gastrointestinal tissues and to prevent lethal bacterial infections in animal models of radiation damage.

3 Dec 2009

CT imaging after chemotherapy with bevacizumab may help predict overall survival

Preliminary research suggests that criteria based on computed tomography (CT) imaging of changes in tumors from colorectal liver metastases after chemotherapy with the drug bevacizumab may have the potential to predict overall survival, according to a study in the December 2 issue of JAMA.

3 Dec 2009

Earlier diagnosis of cancer saves 5,000 to 10,000 lives each year, says Professor Mike Richards

Earlier diagnosis of people with cancer could save between 5,000 and 10,000 lives each year, Professor Mike Richards, the National Cancer Director for England, has claimed.

3 Dec 2009

Coding guidelines for Agendia's MammaPrint test established by Palmetto GBA

Agendia, a world leader in molecular cancer diagnostics, announced today that Palmetto GBA, California's Part B Medicare administrator, has established coding guidelines for the company's MammaPrint test.

2 Dec 2009

New data demonstrating the strength of Novartis' hematology portfolio to be presented

Novartis announced today that new data, including a late-breaking presentation on Tasigna® (nilotinib) 200 mg capsules in a form of chronic myeloid leukemia, demonstrate the strength of the company's hematology portfolio in advancing the care of patients.

2 Dec 2009

Researchers attribute modest improvement in lung cancer patients to novel targeted therapies

Research released in the December 2009 issue of the Journal of Thoracic Oncology sought to determine whether the survival improvement among patients with metastatic lung cancer has improved over the last two decades as reported in controlled clinical trials.

2 Dec 2009

Human Melanoma Research Team pursuing identification of anti-tumor prognostic markers and drugs

The constant increase in the rate of cutaneous melanoma over recent years and its resistance to anti-tumour pharmaceutical drugs has meant that the study of cutaneous melanoma is one of the greatest scientific challenges in the field of cancer. The Human Melanoma research team at the University of the Basque Country (UPV/EHU) is focusing on this study.

2 Dec 2009

Development of novel virus can lead to new therapeutic strategy to combat cancer

Ohio State University cancer researchers have developed a tumor-attacking virus that both kills brain-tumor cells and blocks the growth of new tumor blood vessels.

2 Dec 2009

CT imaging combined with Avastin may predict overall survival in metastatic colorectal cancer

Using routine computed tomography (CT) imaging to analyze form and structural changes to colorectal liver metastasis after bevacizumab and chemotherapy may predict overall survival, according to research from The University of Texas M. D. Anderson Cancer Center.

2 Dec 2009

Cancer researchers find a way to turn ineffective new cancer drugs into cancer-fighters

Cancer researchers at the University of Oklahoma Health Sciences Center have found a way to turn ineffective new cancer drugs into cancer-fighters. By using their patented chemical compound, SHetA2, researchers tricked cancer cells into responding to new treatments and undergoing cell suicide.

2 Dec 2009

New data on pixantrone Phase III trial in non-Hodgkin's lymphoma to be presented

Cell Therapeutics, Inc. (CTI) announced today that Ruth Pettengell, M.D. of St. George's Hospital, University of London, the lead investigator for the PIX 301 EXTEND trial will present new data on the pixantrone phase III trial in relapsed/refractory aggressive non-Hodgkin's lymphoma (NHL) at the 51st Annual Meeting of the American Society of Hematology on Saturday, December 5, 2009 in New Orleans, Louisiana.

2 Dec 2009

Results from ongoing clinical trial of ISF35 to be presented at ASH annual meeting

Memgen announced today that results from its ongoing, Leukemia & Lymphoma Society co-sponsored clinical trial in chronic lymphocytic leukemia (CLL) have been selected for an oral presentation at the 51st Annual Meeting of the American Society of Hematology (ASH) in New Orleans, Louisiana.

2 Dec 2009

CRO to run CEL-SCI's upcoming Phase III clinical trial

CEL-SCI Corporation, a late-stage oncology company and a developer of vaccines and therapeutics for the prevention and treatment of infectious diseases, announced today that it has retained the services of an international Contract Research Organization (CRO) to run CEL-SCI's upcoming Phase III clinical trial in advanced primary head and neck cancer with the Company's lead product candidate, Multikine®.

1 Dec 2009

Acceleron Pharma announces study results of its ACE-011 and ACE-536 blood forming agents

Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including red blood cells, bone, muscle, fat, and the vasculature, today announced that results from preclinical and clinical studies of two, novel blood forming agents, ACE-011 and ACE-536, will be presented at the 51st Annual Meeting of the American Society of Hematology at the Ernest N. Morial Convention Center in New Orleans, Louisiana.

1 Dec 2009

Teva Pharmaceutical Industries submits a BLA for its G-CSF XM02

Teva Pharmaceutical Industries Ltd., today announced the submission of a Biologics License Application (BLA) with the U.S. Food and Drug Administration (FDA) for XM02, a granulocyte colony-stimulating factor (G-CSF) for the reduction in the duration of severe neutropenia and the incidence of febrile neutropenia in patients treated with established myelosuppressive chemotherapy for cancer.

1 Dec 2009

Chemotherapy News and Research

Latest Chemotherapy News and Research

The Cancer Center at Harrington receives approval to treat its first patients

Update on European commercial launch of MuGard for oral mucositis provided

Don't stop dieting during the holiday season

Allos Therapeutics to launch the COMPLETE registry for patients with PTCL

Update on Celsion's ThermoDox Phase III “HEAT” trial for HCC

PEG polymer may prevent GI injury during cancer radiotherapy

CT imaging after chemotherapy with bevacizumab may help predict overall survival

Earlier diagnosis of cancer saves 5,000 to 10,000 lives each year, says Professor Mike Richards

Coding guidelines for Agendia's MammaPrint test established by Palmetto GBA

New data demonstrating the strength of Novartis' hematology portfolio to be presented

Researchers attribute modest improvement in lung cancer patients to novel targeted therapies

Human Melanoma Research Team pursuing identification of anti-tumor prognostic markers and drugs

Development of novel virus can lead to new therapeutic strategy to combat cancer

CT imaging combined with Avastin may predict overall survival in metastatic colorectal cancer

Cancer researchers find a way to turn ineffective new cancer drugs into cancer-fighters

New data on pixantrone Phase III trial in non-Hodgkin's lymphoma to be presented

Results from ongoing clinical trial of ISF35 to be presented at ASH annual meeting

CRO to run CEL-SCI's upcoming Phase III clinical trial

Acceleron Pharma announces study results of its ACE-011 and ACE-536 blood forming agents

Teva Pharmaceutical Industries submits a BLA for its G-CSF XM02

Cancer Research - Second Edition eBook

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

How cohesin mechanics and nanotracker tech are redefining DNA research

Chemotherapy News and Research

Latest Chemotherapy News and Research

Cancer Research - Second Edition eBook

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

How cohesin mechanics and nanotracker tech are redefining DNA research

Newsletters you may be interested in